Recent price performance and business profile

Kymera Therapeutics (KYMR) has drawn attention after a recent pullback, with the stock down 9.2% over the past day and 11.7% over the past week. This has invited closer scrutiny of its underlying business.

The US based clinical stage biopharmaceutical company focuses on small molecule therapeutics that degrade disease causing proteins. It applies this approach across immunology, inflammation, and oncology indications through multiple clinical programs.

Despite the sharp pullback in the last week, with a 7 day share price return of down 11.7% and a 90 day share price return of down 17.2%, Kymera Therapeutics still shows a 1 year total shareholder return of 63.6%. This suggests recent momentum has cooled after a strong longer term run.

If you are looking beyond a single biotech story, this could be a good moment to broaden your watchlist with 39 healthcare AI stocks

With Kymera still loss making, carrying a value score of 2 and trading well below published analyst targets, you have to ask: is the recent pullback setting up a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 48.3% Undervalued

The most followed narrative values Kymera Therapeutics at $138 per share, compared with the last close of $71.29, framing a steep implied discount that hinges on ambitious long term assumptions.

Expansion of a best in industry oral immunology franchise, including the first in class IRF5 degrader KT-579 and a follow on STAT6 molecule kept IND ready, creates a durable competitive moat in novel oral mechanisms that can support multiple high value launches and structurally higher earnings over time.

Want to see what kind of revenue curve and margin shift would need to sit behind that $138 figure? The narrative leans on fast top line growth, a sharp swing toward industry type profitability, and a future earnings multiple that is anything but ordinary. Curious how those pieces are stitched together into one valuation story.

Result: Fair Value of $138 (UNDERVALUED)

However, this upbeat story can unravel quickly if key trials disappoint or if partner decisions reduce potential milestone inflows that support the high implied valuation.

Another angle on valuation

The bullish fair value of $138 leans heavily on aggressive revenue and margin assumptions. On a simpler yardstick, Kymera trades at a P/B of 3.8x, richer than the US Biotechs industry at 2.6x but far below a 24.4x peer average. Is the stock pricing in too much, or not enough?

Next Steps

If this mix of optimism and concern feels familiar, that is the point. You need to look at the data yourself and weigh both sides of the story with 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If Kymera has your attention, do not stop here. Broaden your opportunity set now so you are not relying on a single stock to carry your thesis.

• Target potential mispricings by scanning companies that combine quality fundamentals with discounted valuations using the 46 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by focusing on companies with healthier finances through the solid balance sheet and fundamentals stocks screener (47 results).
• Get ahead of the crowd by reviewing a screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.